Recent news
Discover our latest research and publications
Discover our latest research and publications
A Perspective on Biomarkers, Candidates for Surrogate End Points to Accelerate Successful Development of New Antiparasitic Agents for the Treatment of Chronic Chagas Disease
A New Breakthrough in Understanding Biomarkers of Severe Infection: The Role of Neutralizing Autoantibodies Directed Against IL-1Ra in Severe Community-Acquired Bacterial Pneumonia
A new study revealing that MultiCruzi enables the early assessment of treatment-associated biological responses in adults with Chagas disease, with antibody decline serving as an exploratory pharmacodynamic marker
Our research study on evaluating treatment efficacy in adult Chagas patients is published in Nature.
InfYnity Biomarkers' groundbreaking research on Chagas disease is featured in the DNDi Chagas Platform Newsletter - Page 6
Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects
InfYnity Biomarkers and Quotient Limited Announce Partnership to Expand MosaiQ Infectious Disease Menu
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
Our Lancet Infectious disease article on 'Chagas therapy monitoring' is highlighted in the DNDi Chagas Platform Newsletter - Page 8
Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study
InfYnity Multiplex ELISA Platform: Reliable & Highly Reproducible
Contact Info
INFYNITY BIOMARKERS
78-80 rue du Bourbonnais
69009 Lyon – France
Tel: +33 4 72 76 20 29
Email: contact@infynity-biomarkers.com
Read the Legal notice